Genocea Biosciences Inc. buy Quitte
Summary
This prediction ended on 22.05.19 with a price of €4.12. The prediction for Genocea Biosciences Inc. disappointed with a performance of -22.84%. Quitte has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | -0.268% | 5.471% | 14.271% | 19.027% |
iShares Nasdaq 100 | 1.854% | 7.851% | 35.426% | 58.415% |
iShares Nikkei 225® | 0.284% | 1.729% | 9.943% | 7.045% |
iShares S&P 500 | 1.178% | 5.269% | 27.989% | 49.400% |
Comments by Quitte for this prediction
In the thread Genocea Biosciences Inc. diskutieren
geh wieder rein
Quitte stimmt am 08.04.2019 dem Buy-Gesamtsentiment mit dem Kursziel 1.0$ zu.
Stopped prediction by Quitte for Genocea Biosciences Inc.
Genocea Biosciences Inc.
05.01.21
05.01.22
06.01.22
Genocea Biosciences Inc.
05.06.18
05.12.18
05.12.18